View Past PerformanceThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsEvoke Pharma 대차대조표 건전성재무 건전성 기준 점검 6/6Evoke Pharma 의 총 주주 지분은 $3.4M 이고 총 부채는 $5.0M, 이는 부채 대 자기자본 비율을 148.7% 로 가져옵니다. 총자산과 총부채는 각각 $15.6M 및 $12.3M 입니다.핵심 정보148.71%부채/자본 비율US$5.00m부채이자보상배율n/a현금US$11.58m자본US$3.36m총부채US$12.29m총자산US$15.65m최근 재무 건전성 업데이트Evoke Pharma (NASDAQ:EVOK) Is Using Debt SafelyJul 30Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementAug 02Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)Feb 26Evoke Pharma Announces Update on Non-Compliance Notice from NasdaqNov 29Evoke Pharma Receives Notice from NasdaqNov 23Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain ComplianceJul 23모든 업데이트 보기Recent updatesEvoke Pharma, Inc.(NasdaqCM:EVOK) dropped from NASDAQ Composite IndexDec 18QOL Medical, LLC completed the acquisition of Evoke Pharma, Inc. (NasdaqCM:EVOK).Dec 17Third quarter 2025 earnings: Revenues and EPS in line with analyst expectations Nov 16 Nov 14QOL Medical, LLC entered into a definitive agreement to acquire Evoke Pharma, Inc. (NasdaqCM:EVOK) for $18.9 million.Nov 05New major risk - Market cap size Oct 02Consensus EPS estimates fall by 94% Aug 21Investors Still Aren't Entirely Convinced By Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Despite 31% Price JumpAug 19Second quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 15Evoke Pharma, Inc. Confirms Sales Guidance for the Year 2025Aug 14Evoke Pharma (NASDAQ:EVOK) Is Using Debt SafelyJul 30Evoke Pharma, Inc. Receives Notice of Allowance for U.S. Patent Application for Gimoti Extending Orange Book listings to 2036Jul 10New major risk - Share price stability Jul 09Evoke Pharma, Inc. (NASDAQ:EVOK) Might Not Be As Mispriced As It Looks After Plunging 27%Jun 22Consensus EPS estimates fall by 25% May 20First quarter 2025 earnings: Revenues miss analyst expectations May 16Evoke Pharma, Inc. Reiterates Earnings Guidance for the Year 2025May 14Evoke Pharma, Inc., Annual General Meeting, May 21, 2025Apr 11Consensus revenue estimates fall by 20% Mar 20Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% LowerMar 16Forecast breakeven date pushed back to 2026 Mar 14Evoke Pharma, Inc. Provides Revenue Guidance for 2025Mar 14Evoke Pharma, Inc. to Report Q4, 2024 Results on Mar 13, 2025Mar 06Evoke Pharma Announces Appointment of Greg Pyszczymuka to the Board of DirectorsFeb 24Consensus revenue estimates fall by 12% Nov 14Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 10Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024Nov 09Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II DirectorOct 22Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.Aug 30New major risk - Share price stability Aug 22Consensus revenue estimates fall by 17% Aug 20Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024Aug 15Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 14Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementAug 02Consensus EPS estimates upgraded to US$0.08 loss, revenue downgraded May 21First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 16Evoke Pharma, Inc., Annual General Meeting, May 22, 2024Apr 11Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024Mar 22+ 1 more updateFull year 2023 earnings released Mar 16Evoke Pharma, Inc. Provides Earnings Guidance for 2024Mar 15New major risk - Revenue and earnings growth Mar 15Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024Mar 08Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)Feb 26New major risk - Shareholder dilution Feb 10Evoke Pharma, Inc. has completed a Follow-on Equity Offering.Feb 09Evoke Pharma Announces Update on Non-Compliance Notice from NasdaqNov 29Evoke Pharma Receives Notice from NasdaqNov 23Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.Nov 11Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022) Nov 11New major risk - Revenue and earnings growth Nov 10Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTINov 03Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTISep 15Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 11Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain ComplianceJul 23Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital MarketMay 29Consensus EPS estimates fall by 13% May 22First quarter 2023 earnings: EPS and revenues miss analyst expectations May 17Consensus EPS estimates fall by 57% Mar 28Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 22Evoke Pharma, Inc. Announces Executive ChangesFeb 14Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against GimotiJan 31Evoke Pharma (NASDAQ:EVOK) Is Using Debt SafelyJan 22Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023Jan 19Price target decreased to US$7.00 Nov 16Consensus revenue estimates increase by 25% Nov 16Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11Evoke to get US patent for nasal spray Gimoti Sep 20Consensus revenue estimates fall by 19% Aug 17Price target decreased to US$63.50 Aug 12Evoke Pharma Q2 GAAP loss per share narrows, revenue up Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray Jul 06Price target decreased to US$6.50 May 22Consensus EPS estimates fall by 29% May 17No longer forecast to breakeven May 12Price target increased to US$9.50 Apr 27Insufficient new directors Mar 17Consensus forecasts updated Mar 15No longer forecast to breakeven Mar 09Price target increased to US$9.50 Jan 26Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?Oct 22Consensus revenue estimates increase to US$1.28m Aug 19Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?Jul 06재무 상태 분석단기부채: EVOK 의 단기 자산 ( $15.5M )이 단기 부채( $12.2M ).장기 부채: EVOK의 단기 자산($15.5M)이 장기 부채($46.4K)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: EVOK 총 부채보다 더 많은 현금을 보유하고 있습니다.부채 감소: EVOK는 5년 전 마이너스 주주 지분이었으나 현재 플러스로 개선되었습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: EVOK 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: EVOK 무료 현금 흐름이 역사적 비율인 7.5 로 계속 증가할 경우 2.5 년 동안 충분한 현금 활주로를 보유하고 있습니다. 7.5 % 매년.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/18 08:29종가2025/12/16 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Evoke Pharma, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Edward WooAscendiant Capital Markets LLCDavid BuckB. Riley Securities, Inc.Irina Rivkind KofflerCantor Fitzgerald & Co.4명의 분석가 더 보기
Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementAug 02
Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)Feb 26
QOL Medical, LLC entered into a definitive agreement to acquire Evoke Pharma, Inc. (NasdaqCM:EVOK) for $18.9 million.Nov 05
Investors Still Aren't Entirely Convinced By Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Despite 31% Price JumpAug 19
Evoke Pharma, Inc. Receives Notice of Allowance for U.S. Patent Application for Gimoti Extending Orange Book listings to 2036Jul 10
Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementAug 02
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024Mar 22+ 1 more update
Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)Feb 26
Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTISep 15
Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital MarketMay 29
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023Jan 19